Eine diesen Monat in der Fachzeitschrift „Cause and Control of Cancer“ veröffentlichte Studie ergab, dass bei Patienten, die Metformin einnahmen, eine geringere Inzidenz von Leberkrebs auftrat als bei Patienten, die alternative Antidiabetika einnahmen.
Although other previous studies have found an association between metformin and reduced risk of several cancer types, most studies are affected by multiple factors, such as deviations related to treatment time differences between cases and controls, as well as body mass index and glycemic control And other factors. The researchers in this study strictly controlled these factors in the study of diabetic patients in the National Veterans Health Management Database. They found that the use of metformin was not associated with the incidence of 10 solid tumor types (except Leberkrebs).
Diese Studie legt nahe, dass Metformin weiter klinisch untersucht werden sollte, um den Zweck der Leberkrebsprävention zu erreichen.
